UK medical group rejects new skin cancer treatment

By MARIA CHENG , AP Medical Writer

(AP) -- An independent British medical watchdog says the first treatment proven to help people with the deadliest form of skin cancer is too expensive to be used by the U.K.'s health care system, a recommendation critics called a potential death sentence.

The drug, Bristol-Myers Squibb's Yervoy, has offered some hope to people with advanced skin cancers, though a study of patients with advanced, inoperable showed it extended survival only four months on average.

The National Institute for Clinical Excellence, or NICE, advised Friday that at a cost of 80,000 pounds ($126,600) Yervoy "could not be considered a cost-effective use" of health funds. A final decision is expected next month after a public consultation.

In the U.K., most medicines are paid for by the government, as long as they're recommended by the cost-efficiency watchdog. The agency commonly rejects expensive drugs, including recently advising against new treatments for , , and multiple sclerosis, though patients and doctors are increasingly protesting the decisions.

The government usually adopts NICE's recommendations, meaning doctors in the government-funded health service cannot prescribe Yervoy without NICE's approval.

In its decision, NICE said it was not convinced by the evidence, saying the data for Yervoy, which works by stimulating the immune system to fight , did not compare it to older drugs used to treat melanoma. NICE also said the trial was too short to know how long the drug's effects would last and raised concerns about the drug's side effects, including diarrhea, rash, fatigue and nausea, which they said could affect a patient's quality of life.

"We need to be sure that new treatments provide sufficient benefits to justify the significant cost (the ) is being asked to pay," said Sir Andrew Dillon, NICE's chief executive, in a statement.

and charities slammed the decision, labeling it a "" for people with advanced skin cancer.

"The breakthrough that patients and clinicians throughout the U.K. have been waiting for arrived in the form of this drug," said patient advocacy group Factor 50 and the charity SKCIN, in a statement. "To have come so close to a breakthrough and to be told no at this stage is truly devastating."

Drugmaker Bristol-Myers will provide additional evidence in hopes that the agency "will reconsider this decision so that all patients with metastatic melanoma can access this potentially life-extending treatment," European vice president Amadou Diarra said in a statement.

NICE does not usually approve any treatments that cost more than 30,000 pounds (US$47,492) to buy an extra healthy year of life, though it does occasionally make exceptions for lifesaving therapies.

In recent years, NICE has been forced to overturn a number of its original judgments after public outcry. "They actually reverse their decisions quite a lot," said Aparna Krishnan, a senior health care and pharmaceutical analyst at IHS Global Insight in London.

In 2005, the agency refused to recommend Alzheimer's drugs including Aricept. Public protests forced a reconsideration, and the drugs were finally recommended to all Alzheimer's patients last year. In addition, NICE has reversed its decisions on drugs including the kidney cancer drug Sutent, the flu drug Relenza, Velcade for blood cancer, and Herceptin for stomach cancer.

NICE has also been criticized for taking too long to recommend drugs. After Herceptin was first approved for breast cancer, the agency had to scramble to speed up its evaluation process after several women sued their hospitals to get treatment before advice was issued.

Some analysts said the spiraling cost of specialized cancer drugs would mean fewer hospitals and insurers willing to pay for them - particularly those with cash-strapped public health systems.

"Drug companies, meet reality," said Erik Gordon, an analyst and professor at University of Michigan's Ross School of Business. "There isn't enough money to pay $100,000 for therapies that don't show massive benefits, unless there is a politically powerful patient advocacy group behind it."

Analyst Krishnan said she wasn't sure if patient and doctor protests would ultimately convince NICE to recommend Yervoy, but acknowledged it was a possibility. "They are in a very difficult position," she said. "They are increasingly just looking at the cost, but the pressure from the public can be very powerful."

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Bristol-Myers pitches its cancer medicine pipeline

Jun 06, 2011

(AP) -- Bristol-Myers Squibb Co. executives said Monday they have more than a half-dozen drugs in testing against different cancers and could get important data on them and possibly a couple of approvals this year.

FDA clears first melanoma drug to extend life

Mar 25, 2011

(AP) -- The Food and Drug Administration has approved a breakthrough cancer medication from Bristol-Myers Squibb Co. that researchers have heralded as the first drug to prolong the lives of patients with ...

Studies find new drugs boost skin cancer survival

Jun 06, 2011

(AP) -- They're not cures, but two novel drugs produced unprecedented gains in survival in separate studies of people with melanoma, the deadliest form of skin cancer, doctors reported Sunday.

Recommended for you

Scientists to use tiny particles to fight big diseases

1 hour ago

Physicians will tell you: They are not winning the war on ovarian cancer. But FIU researchers are crafting a new weapon for that battle. A group of scientists have combined medicine and advanced nanotechnological engineering ...

Popular prostate cancer therapy may be harmful

5 hours ago

A widely used treatment for prostate cancer may cause more harm than good for some patients, according to Dr. Oliver Sartor, medical director of the Tulane Cancer Center.

User comments